hotspot -WSS

hotspot

author：fashion 2025-08-26 10:52:11 - browse：5

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Flagship, Pfizer team up in deal worth up to $7 billion

focus

WSS

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Manchin plays down potential 3rd

Twill hunts for pharma partner to market its depression app

Listen: Biogen's messy board & Laronde's data problem

Why you get paid to donate plasma but not blood

Pfizer's Covid pill remains 89% effective in final analysis, company says

explore

hotspot

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Connecting traumatic brain injury and domestic violence

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

RaDonda Vaught case: a double standard for nurses, physicians

Cancer drug shortages should be causing more outrage

When is a doctor not a doctor? Try when patients address women doctors

Wildfire smoke exposes gaps in outdoor worker protections

House passes resolution saying Israel isn't a 'racist or apartheid state'

Novavax promises a turnaround & Lilly roils the obesity market

US soldier in North Korean custody after crossing DMZ line

focus

Doctor appointment wait times are getting worse

Johnson & Johnson sues to stop Medicare negotiation

BridgeBio heart drug succeeds in pivotal study

A look at other Americans who have crossed into North Korea over the years

Flagship, Pfizer team up in deal worth up to $7 billion

Listen: Biogen's messy board & Laronde's data problem

focus

focus

focus

entertainment